Centre Daily -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative new medicines targeting microRNAs, today announced it is collaborating with researchers at the University of California, San Diego (UCSD) School of Medicine seeking novel treatments for angiogenic diseases using microRNA therapeutics. The research will combine Regulus’ leading microRNA platform with UCSD’s expertise in animal models of angiogenesis to discover anti-angiogenic microRNA-targeted therapies that could be rapidly translated for treatment of human disease. The collaborative research program was the recent recipient of a UC Discovery Grant that promotes collaborations between the university’s researchers and industry partners. Financial terms of the grant were not disclosed.
